News
08-24-2015, 05:26 AM
Esperance Pharmaceuticals Inc. today announced that it has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer candidate EP-100 for the treatment of ovarian cancer and to collaborate on preclinical studies of EP-100 as a treatment for breast cancer.
More... (http://www.news-medical.net/news/20150824/Esperance-MD-Anderson-form-strategic-alliance-to-accelerate-development-of-anti-cancer-candidate-EP-100.aspx)
More... (http://www.news-medical.net/news/20150824/Esperance-MD-Anderson-form-strategic-alliance-to-accelerate-development-of-anti-cancer-candidate-EP-100.aspx)